Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
germ cell tumor
microRNA
retroperitoneal lymph node dissection
serum biomarker
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
01
09
2022
received:
09
06
2022
accepted:
30
09
2022
medline:
4
4
2023
pubmed:
19
10
2022
entrez:
18
10
2022
Statut:
ppublish
Résumé
Conventional serum tumor markers (STMs) for testicular germ cell tumors (GCTs) offer limited performance with particularly poor sensitivity in cases of minimal residual disease and pure seminoma. While growing evidence has indicated miR-371a-3p to be a superior biomarker, its utility in detecting pure seminoma at recurrence has not been extensively explored. This study's objective was to explore miR-371a-3p's utility in detecting metastatic pure seminoma at retroperitoneal lymph node dissection (RPLND). RNA was isolated from patient serum samples collected pre-RPLND. Fifteen patients were assigned to our 'benign' (n = 6) or 'seminoma' (n = 9) group based on pathological confirmation of viable seminoma. Five of the patients received chemotherapy before RPLND (PC-RPLND), and 10 were chemotherapy naïve. MiR-371a-3p expression was quantified via RT-quantitative polymerase chain reaction. The Cq values were statistically evaluated to obtain performance measurements. Median relative expression of miR-371a-3p was higher in the Seminoma group than the Benign, but this difference was not statistically significant (Rq = 3705 and 241, respectively, p = 0.2844). Of the 10 chemotherapy naïve patients, nine had viable seminoma at RPLND, and seven had elevated miR-371a-3p expression. Among the five postchemotherapy (PC) patients, zero had viable GCT at RPLND, and two had elevated miR-371a-3p expression. The primary RPLND group presented 78% sensitivity and 100% specificity. Specificity in the PC-RPLND group was 60%. An optimal Rq threshold of 28.62 was determined by Youden's J statistic, yielding 78% sensitivity and 67% specificity. Receiver operating characteristic analysis provided an AUC of 0.704 (95% CI: 0.43-0.98, p = 0.1949). Despite modest performance, miR-371a-3p exhibited improved sensitivity and specificity compared with conventional STMs. MiR-371a-3p outperformed STMs in the primary RPLND settings. However, miR-371a-3p was not a robust predictor of pathology in the PC setting. These results suggest that pure seminoma at RPLND is a clinical context, wherein the miRNA assay may require further refinement.
Substances chimiques
MicroRNAs
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
634-640Informations de copyright
© 2022 American Society of Andrology and European Academy of Andrology.
Références
Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology. 2015;3(1):4-12. https://doi.org/10.1111/andr.293. PubMed PMID: 25331326; PubMed Central PMCID: PMCPMC4410839.
Fung C, Fossa SD, Williams A, Travis LB. Long-term morbidity of testicular cancer treatment. Urol Clin North Am. 2015;42(3):393-408. https://doi.org/10.1016/j.ucl.2015.05.002. PubMed PMID: 26216826.
Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol. 2010;7(11):610-617. https://doi.org/10.1038/nrurol.2010.166. PubMed PMID: 21068762.
Bagrodia A, Savelyeva A, Lafin JT, et al. Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. BJU Int. 2021;128(1):57-64. https://doi.org/10.1111/bju.15288. PubMed PMID: 33124175.
Wymer KM, Pearce SM, Harris KT, Pierorazio PM, Daneshmand S, Eggener SE. Adherence to National Comprehensive Cancer Network® guidelines for testicular cancer. J Urol. 2017;197(3 Pt 1):684-689. https://doi.org/10.1016/j.juro.2016.09.073. PubMed PMID: 27663460.
Dieckmann KP, Radtke A, Geczi L, et al. Serum levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol. 2019;37(16):1412-1423. https://doi.org/10.1200/jco.18.01480. PubMed PMID: 30875280; PubMed Central PMCID: PMCPMC6544462.
Murray MJ, Scarpini CG, Coleman N. A circulating MicroRNA panel for malignant germ cell tumor diagnosis and monitoring. Methods Mol Biol. 2021;2195:225-243. https://doi.org/10.1007/978-1-0716-0860-9_15. PubMed PMID: 32852767.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35. https://doi.org/10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. PubMed PMID: 15405679.
Ghandour RA, Singla N, Bagrodia A. Management of stage II germ cell tumors. Urol Clin North Am. 2019;46(3):363-376. https://doi.org/10.1016/j.ucl.2019.04.002. PubMed PMID: 31277731.
Decoene J, Winter C, Albers P. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. Urol Oncol. 2015;33(1):23.e15-23 e1. https://doi.org/10.1016/j.urolonc.2014.09.019. PubMed PMID: 25454484.
Lafin JT, Singla N, Woldu SL, et al. Serum MicroRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naive patients undergoing retroperitoneal lymph node dissection. Eur Urol. 2020;77(2):290-292. https://doi.org/10.1016/j.eururo.2019.10.005. PubMed PMID: 31699528.
Leão R, van Agthoven T, Figueiredo A, et al. Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor. J Urol. 2018;200(1):126-135. https://doi.org/10.1016/j.juro.2018.02.068. PubMed PMID: 29474847.
Dieckmann K-P, Klemke M, Grobelny F, et al. Serum levels of MicroRNA-371a-3p (M371) can predict absence or presence of vital disease in residual masses after chemotherapy of metastatic seminoma. Front Oncol. 2022;12:889624. https://doi.org/10.3389/fonc.2022.889624
Dieckmann K-P, Radtke A, Geczi L, et al. Serum levels of MicroRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol. 2019;37(16):1412-1423. https://doi.org/10.1200/JCO.18.01480
Myklebust MP, Thor A, Rosenlund B, et al. Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study. Sci Rep. 2021;11(1):15582. https://doi.org/10.1038/s41598-021-94812-2